Urinary estrogen metabolites and breast cancer

A combined analysis of individual level data

Cher M. Dallal, Roslyn A. Stone, Jane A. Cauley, Roberta B. Ness, Victor G. Vogel, Ian S. Fentiman, Jay Fowke, Vittorio Krogh, Steffen Loft, Elaine N. Meilahn, Paola Muti, Anja Olsen, Kim Overvad, Sabina Sieri, Anne Tjønneland, Giske Ursin, Anja Wellejus, Emanuela Taioli

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background: Circulating estrogens are associated with increased breast cancer risk, yet the role of estrogen metabolites in breast carcinogenesis remains unclear. This combined analysis of 5 published studies evaluates urinary 2-hydroxyestrone (2- OHE1), 16α-hydroxyestrone (16α-OHE1), and their ratio (2:16α-OHE1) in relation to breast cancer risk. Methods: Primary data on 726 premenopausal women (183 invasive breast cancer cases and 543 controls) and 1,108 postmenopausal women (385 invasive breast cancer cases and 723 controls) were analyzed. Urinary estrogen metabolites were measured using enzyme linked immunosorbent assays. Study-specific and combined multivariable adjusted odds ratios (ORs) and 95% confidence intervals (CIs) were estimated based on tertiles of estrogen metabolites. Multinomial logistic regression models were fit according to hormone receptor status. Results: Higher premenopausal 2:16α-OHE1 was suggestive of reduced breast cancer risk overall (study-adjusted ORIIIvsI=0.80; 95% CI: 0.49-1.32) and for estrogen receptor negative (ER-) subtype (ORIIIvsI=0.33; 95% CI: 0.13-0.84). Among postmenopausal women, 2:16α-OHE1 was unrelated to breast cancer risk (study-adjusted ORIIIvsI=0.93; 95% CI: 0.65-1.33); however, the association between 2-OHE1 and risk varied by body mass index (p-interaction=0.003). Conclusions: Premenopausal urinary 2:16α-OHE1 may play a role in breast carcinogenesis; however, larger studies are needed. Our findings do not support reduced breast cancer risk with higher postmenopausal 2:16α-OHE1 overall, although obesity may modify associations with 2-OHE1.

Original languageEnglish (US)
Pages (from-to)3-16
Number of pages14
JournalInternational Journal of Biological Markers
Volume28
Issue number1
DOIs
StatePublished - Jan 1 2013
Externally publishedYes

Fingerprint

Metabolites
Estrogens
Breast Neoplasms
Confidence Intervals
Carcinogenesis
Breast
Logistic Models
Immunosorbents
Estrogen Receptors
Logistics
Assays
Association reactions
Hormones
Body Mass Index
Obesity
Enzyme-Linked Immunosorbent Assay
Odds Ratio
Enzymes

All Science Journal Classification (ASJC) codes

  • Pathology and Forensic Medicine
  • Oncology
  • Clinical Biochemistry
  • Cancer Research

Cite this

Dallal, C. M., Stone, R. A., Cauley, J. A., Ness, R. B., Vogel, V. G., Fentiman, I. S., ... Taioli, E. (2013). Urinary estrogen metabolites and breast cancer: A combined analysis of individual level data. International Journal of Biological Markers, 28(1), 3-16. https://doi.org/10.5301/JBM.2012.9353

Urinary estrogen metabolites and breast cancer : A combined analysis of individual level data. / Dallal, Cher M.; Stone, Roslyn A.; Cauley, Jane A.; Ness, Roberta B.; Vogel, Victor G.; Fentiman, Ian S.; Fowke, Jay; Krogh, Vittorio; Loft, Steffen; Meilahn, Elaine N.; Muti, Paola; Olsen, Anja; Overvad, Kim; Sieri, Sabina; Tjønneland, Anne; Ursin, Giske; Wellejus, Anja; Taioli, Emanuela.

In: International Journal of Biological Markers, Vol. 28, No. 1, 01.01.2013, p. 3-16.

Research output: Contribution to journalArticle

Dallal, CM, Stone, RA, Cauley, JA, Ness, RB, Vogel, VG, Fentiman, IS, Fowke, J, Krogh, V, Loft, S, Meilahn, EN, Muti, P, Olsen, A, Overvad, K, Sieri, S, Tjønneland, A, Ursin, G, Wellejus, A & Taioli, E 2013, 'Urinary estrogen metabolites and breast cancer: A combined analysis of individual level data', International Journal of Biological Markers, vol. 28, no. 1, pp. 3-16. https://doi.org/10.5301/JBM.2012.9353
Dallal, Cher M. ; Stone, Roslyn A. ; Cauley, Jane A. ; Ness, Roberta B. ; Vogel, Victor G. ; Fentiman, Ian S. ; Fowke, Jay ; Krogh, Vittorio ; Loft, Steffen ; Meilahn, Elaine N. ; Muti, Paola ; Olsen, Anja ; Overvad, Kim ; Sieri, Sabina ; Tjønneland, Anne ; Ursin, Giske ; Wellejus, Anja ; Taioli, Emanuela. / Urinary estrogen metabolites and breast cancer : A combined analysis of individual level data. In: International Journal of Biological Markers. 2013 ; Vol. 28, No. 1. pp. 3-16.
@article{3d5da5756a194290bcfd3aa30976abb6,
title = "Urinary estrogen metabolites and breast cancer: A combined analysis of individual level data",
abstract = "Background: Circulating estrogens are associated with increased breast cancer risk, yet the role of estrogen metabolites in breast carcinogenesis remains unclear. This combined analysis of 5 published studies evaluates urinary 2-hydroxyestrone (2- OHE1), 16α-hydroxyestrone (16α-OHE1), and their ratio (2:16α-OHE1) in relation to breast cancer risk. Methods: Primary data on 726 premenopausal women (183 invasive breast cancer cases and 543 controls) and 1,108 postmenopausal women (385 invasive breast cancer cases and 723 controls) were analyzed. Urinary estrogen metabolites were measured using enzyme linked immunosorbent assays. Study-specific and combined multivariable adjusted odds ratios (ORs) and 95{\%} confidence intervals (CIs) were estimated based on tertiles of estrogen metabolites. Multinomial logistic regression models were fit according to hormone receptor status. Results: Higher premenopausal 2:16α-OHE1 was suggestive of reduced breast cancer risk overall (study-adjusted ORIIIvsI=0.80; 95{\%} CI: 0.49-1.32) and for estrogen receptor negative (ER-) subtype (ORIIIvsI=0.33; 95{\%} CI: 0.13-0.84). Among postmenopausal women, 2:16α-OHE1 was unrelated to breast cancer risk (study-adjusted ORIIIvsI=0.93; 95{\%} CI: 0.65-1.33); however, the association between 2-OHE1 and risk varied by body mass index (p-interaction=0.003). Conclusions: Premenopausal urinary 2:16α-OHE1 may play a role in breast carcinogenesis; however, larger studies are needed. Our findings do not support reduced breast cancer risk with higher postmenopausal 2:16α-OHE1 overall, although obesity may modify associations with 2-OHE1.",
author = "Dallal, {Cher M.} and Stone, {Roslyn A.} and Cauley, {Jane A.} and Ness, {Roberta B.} and Vogel, {Victor G.} and Fentiman, {Ian S.} and Jay Fowke and Vittorio Krogh and Steffen Loft and Meilahn, {Elaine N.} and Paola Muti and Anja Olsen and Kim Overvad and Sabina Sieri and Anne Tj{\o}nneland and Giske Ursin and Anja Wellejus and Emanuela Taioli",
year = "2013",
month = "1",
day = "1",
doi = "10.5301/JBM.2012.9353",
language = "English (US)",
volume = "28",
pages = "3--16",
journal = "International Journal of Biological Markers",
issn = "0393-6155",
publisher = "Wichtig Publishing",
number = "1",

}

TY - JOUR

T1 - Urinary estrogen metabolites and breast cancer

T2 - A combined analysis of individual level data

AU - Dallal, Cher M.

AU - Stone, Roslyn A.

AU - Cauley, Jane A.

AU - Ness, Roberta B.

AU - Vogel, Victor G.

AU - Fentiman, Ian S.

AU - Fowke, Jay

AU - Krogh, Vittorio

AU - Loft, Steffen

AU - Meilahn, Elaine N.

AU - Muti, Paola

AU - Olsen, Anja

AU - Overvad, Kim

AU - Sieri, Sabina

AU - Tjønneland, Anne

AU - Ursin, Giske

AU - Wellejus, Anja

AU - Taioli, Emanuela

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Background: Circulating estrogens are associated with increased breast cancer risk, yet the role of estrogen metabolites in breast carcinogenesis remains unclear. This combined analysis of 5 published studies evaluates urinary 2-hydroxyestrone (2- OHE1), 16α-hydroxyestrone (16α-OHE1), and their ratio (2:16α-OHE1) in relation to breast cancer risk. Methods: Primary data on 726 premenopausal women (183 invasive breast cancer cases and 543 controls) and 1,108 postmenopausal women (385 invasive breast cancer cases and 723 controls) were analyzed. Urinary estrogen metabolites were measured using enzyme linked immunosorbent assays. Study-specific and combined multivariable adjusted odds ratios (ORs) and 95% confidence intervals (CIs) were estimated based on tertiles of estrogen metabolites. Multinomial logistic regression models were fit according to hormone receptor status. Results: Higher premenopausal 2:16α-OHE1 was suggestive of reduced breast cancer risk overall (study-adjusted ORIIIvsI=0.80; 95% CI: 0.49-1.32) and for estrogen receptor negative (ER-) subtype (ORIIIvsI=0.33; 95% CI: 0.13-0.84). Among postmenopausal women, 2:16α-OHE1 was unrelated to breast cancer risk (study-adjusted ORIIIvsI=0.93; 95% CI: 0.65-1.33); however, the association between 2-OHE1 and risk varied by body mass index (p-interaction=0.003). Conclusions: Premenopausal urinary 2:16α-OHE1 may play a role in breast carcinogenesis; however, larger studies are needed. Our findings do not support reduced breast cancer risk with higher postmenopausal 2:16α-OHE1 overall, although obesity may modify associations with 2-OHE1.

AB - Background: Circulating estrogens are associated with increased breast cancer risk, yet the role of estrogen metabolites in breast carcinogenesis remains unclear. This combined analysis of 5 published studies evaluates urinary 2-hydroxyestrone (2- OHE1), 16α-hydroxyestrone (16α-OHE1), and their ratio (2:16α-OHE1) in relation to breast cancer risk. Methods: Primary data on 726 premenopausal women (183 invasive breast cancer cases and 543 controls) and 1,108 postmenopausal women (385 invasive breast cancer cases and 723 controls) were analyzed. Urinary estrogen metabolites were measured using enzyme linked immunosorbent assays. Study-specific and combined multivariable adjusted odds ratios (ORs) and 95% confidence intervals (CIs) were estimated based on tertiles of estrogen metabolites. Multinomial logistic regression models were fit according to hormone receptor status. Results: Higher premenopausal 2:16α-OHE1 was suggestive of reduced breast cancer risk overall (study-adjusted ORIIIvsI=0.80; 95% CI: 0.49-1.32) and for estrogen receptor negative (ER-) subtype (ORIIIvsI=0.33; 95% CI: 0.13-0.84). Among postmenopausal women, 2:16α-OHE1 was unrelated to breast cancer risk (study-adjusted ORIIIvsI=0.93; 95% CI: 0.65-1.33); however, the association between 2-OHE1 and risk varied by body mass index (p-interaction=0.003). Conclusions: Premenopausal urinary 2:16α-OHE1 may play a role in breast carcinogenesis; however, larger studies are needed. Our findings do not support reduced breast cancer risk with higher postmenopausal 2:16α-OHE1 overall, although obesity may modify associations with 2-OHE1.

UR - http://www.scopus.com/inward/record.url?scp=84876710718&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876710718&partnerID=8YFLogxK

U2 - 10.5301/JBM.2012.9353

DO - 10.5301/JBM.2012.9353

M3 - Article

VL - 28

SP - 3

EP - 16

JO - International Journal of Biological Markers

JF - International Journal of Biological Markers

SN - 0393-6155

IS - 1

ER -